Literature DB >> 33585557

Long Non-coding RNA BTG3-7:1 and JUND Co-regulate C21ORF91 to Promote Triple-Negative Breast Cancer Progress.

Zheng Dan1, He Xiujing1, Luo Ting2, Zhong Xiaorong2, Zheng Hong2, Yang Jiqiao1, Li Yanchu1, Jing Jing1.   

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is a type of highly invasive breast cancer with poor prognosis. Recently, massive data reveal that long non-coding RNAs (lncRNAs) play important roles in cancer progress. Recently, although the role of lncRNAs in breast cancer has been well documented, few focused on TNBC. In this study, we aimed to systematically identify functional lncRNAs and to explore its molecular mechanism on TNBC progress.
METHODS: The recurrence of lncRNAs and their target genes were validated with TNBC biopsies and cell lines. Total one hundred and thirteen TNBC biopsies, including nineteen patient-matched samples, were collected. The profile of TNBC-related lncRNAs and their target genes were characterized by RNA sequencing (RNA-seq) and bioinformatic analysis. Tumor specific lncRNAs, which also showed biological function correlated with TNBC, were identified as potential candidates; and the target genes, which regulated by the identified lncRNAs, were predicted by the analysis of expression correlation and chromosome colocalization. Cross bioinformatic validation was performed with TNBC independent datasets from the cancer genome atlas (TCGA). The biological functions and molecular mechanism were investigated in TNBC model cell lines by cell colony forming assay, flow cytometry assay, western-blot, RNA Fluorescence in situ Hybridization assay (RNA FISH) and chromatin immunoprecipitation-qPCR (ChIP-qPCR).
RESULTS: Abundant Lnc-BTG3-7:1, which targets gene C21ORF91, was specifically observed in TNBC biopsies and cell lines. Knockdown of Lnc-BTG3-7:1 or C21ORF91 strongly inhibited cell proliferation, promoted cell apoptosis and cell cycle G1-arrested. Meanwhile, investigation of molecular mechanism indicated that Lnc-BTG3-7:1, cooperated with transcription factor JUND, cis-regulated the transcription of C21ORF91 gene, and down-regulation of Lnc-BTG3-7:1/C21ORF91 suppressed GRB2-RAS-RAF-MEK-ERK and GRB2-PI3K-AKT-GSK3β-β-catenin pathways.
CONCLUSIONS: In this study, we identified a TNBC specific lncRNA Lnc-BTG3-7:1, which sustained tumor progress. Up-regulation of Lnc-BTG3-7:1 promoted the transcription of oncogene C21ORF91 and activated PI3K-AKT-GSK3β-β-catenin and MAPK pathways. Taken together, our results not only identified a biomarker for diagnosis but also provided a potential therapeutic target against TNBC.
Copyright © 2021 Dan, Xiujing, Ting, Xiaorong, Hong, Jiqiao, Yanchu and Jing.

Entities:  

Keywords:  C21ORF91 gene; GRB2-PI3K-AKT-GSK3β-β-catenin; GRB2-RAS-RAF-MEK-ERK pathway; Lnc-BTG3-7:1; Triple-negative breast cancer

Year:  2021        PMID: 33585557      PMCID: PMC7879452          DOI: 10.3389/fmolb.2020.605623

Source DB:  PubMed          Journal:  Front Mol Biosci        ISSN: 2296-889X


  54 in total

1.  Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells.

Authors:  Yongguo Shi; Jianwei Lu; Jing Zhou; Xueming Tan; Ye He; Jie Ding; Yun Tian; Li Wang; Keming Wang
Journal:  Biochem Biophys Res Commun       Date:  2014-03-12       Impact factor: 3.575

Review 2.  Long Noncoding RNA and Cancer: A New Paradigm.

Authors:  Arunoday Bhan; Milad Soleimani; Subhrangsu S Mandal
Journal:  Cancer Res       Date:  2017-07-12       Impact factor: 12.701

Review 3.  Homologous recombination deficiency in triple negative breast cancer.

Authors:  Carmen Belli; Bruno Achutti Duso; Emanuela Ferraro; Giuseppe Curigliano
Journal:  Breast       Date:  2019-02-20       Impact factor: 4.380

4.  Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.

Authors:  Rajnish A Gupta; Nilay Shah; Kevin C Wang; Jeewon Kim; Hugo M Horlings; David J Wong; Miao-Chih Tsai; Tiffany Hung; Pedram Argani; John L Rinn; Yulei Wang; Pius Brzoska; Benjamin Kong; Rui Li; Robert B West; Marc J van de Vijver; Saraswati Sukumar; Howard Y Chang
Journal:  Nature       Date:  2010-04-15       Impact factor: 49.962

5.  STRING v10: protein-protein interaction networks, integrated over the tree of life.

Authors:  Damian Szklarczyk; Andrea Franceschini; Stefan Wyder; Kristoffer Forslund; Davide Heller; Jaime Huerta-Cepas; Milan Simonovic; Alexander Roth; Alberto Santos; Kalliopi P Tsafou; Michael Kuhn; Peer Bork; Lars J Jensen; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2014-10-28       Impact factor: 16.971

6.  Estradiol induces HOTAIR levels via GPER-mediated miR-148a inhibition in breast cancer.

Authors:  Sifeng Tao; Haifei He; Qiang Chen
Journal:  J Transl Med       Date:  2015-04-25       Impact factor: 5.531

7.  Programmatic access to bioinformatics tools from EMBL-EBI update: 2017.

Authors:  Szymon Chojnacki; Andrew Cowley; Joon Lee; Anna Foix; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

8.  Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer.

Authors:  Youyou Zhang; Qun He; Zhongyi Hu; Yi Feng; Lingling Fan; Zhaoqing Tang; Jiao Yuan; Weiwei Shan; Chunsheng Li; Xiaowen Hu; Janos L Tanyi; Yi Fan; Qihong Huang; Kathleen Montone; Chi V Dang; Lin Zhang
Journal:  Nat Struct Mol Biol       Date:  2016-04-25       Impact factor: 15.369

9.  CEMiTool: a Bioconductor package for performing comprehensive modular co-expression analyses.

Authors:  Pedro S T Russo; Gustavo R Ferreira; Lucas E Cardozo; Matheus C Bürger; Raul Arias-Carrasco; Sandra R Maruyama; Thiago D C Hirata; Diógenes S Lima; Fernando M Passos; Kiyoshi F Fukutani; Melissa Lever; João S Silva; Vinicius Maracaja-Coutinho; Helder I Nakaya
Journal:  BMC Bioinformatics       Date:  2018-02-20       Impact factor: 3.169

Review 10.  How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.

Authors:  Ji Hyun Park; Jin-Hee Ahn; Sung-Bae Kim
Journal:  ESMO Open       Date:  2018-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.